We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+32.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.65B
AUM Growth
+$1.82B
Cap. Flow
+$94.6M
Cap. Flow %
0.98%
Top 10 Hldgs %
77.89%
Holding
99
New
5
Increased
16
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$37.7M
3
IMVT icon
Immunovant
IMVT
+$22.4M
4
BCAX
Bicara Therapeutics
BCAX
+$21.3M
5
SMMT icon
Summit Therapeutics
SMMT
+$16.8M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$28M
2
LONA
LeonaBio Inc
LONA
+$8.36M
3
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$4.4M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$2.28M
5
SAGE
Sage Therapeutics
SAGE
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 98.95%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
26
Sera Prognostics
SERA
$82.6M
$42.4M 0.44%
5,434,399
– –
CRSP icon
27
CRISPR Therapeutics
CRSP
$4.67B
$39.6M 0.41%
843,075
+743,075
+743% +$37.7M
XENE icon
28
Xenon Pharmaceuticals
XENE
$6.2B
$39.1M 0.41%
993,679
– –
IMVT icon
29
Immunovant
IMVT
$8B
$34.9M 0.36%
1,225,410
+760,692
+164% +$22.4M
CERS icon
30
Cerus
CERS
$581M
$33.9M 0.35%
19,477,339
– –
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.47B
$33.6M 0.35%
1,062,123
– –
ROIV icon
32
Roivant Sciences
ROIV
$23.9B
$32.3M 0.33%
2,798,716
– –
AKRO
33
DELISTED
Akero Therapeutics
AKRO
$31.5M 0.33%
1,097,082
– –
KRYS icon
34
Krystal Biotech
KRYS
$10.7B
$30.9M 0.32%
169,934
– –
CELC icon
35
Celcuity
CELC
$4.07B
$28M 0.29%
1,874,978
– –
GLUE icon
36
Monte Rosa Therapeutics
GLUE
$1.85B
$26.1M 0.27%
4,916,095
– –
DYN icon
37
Dyne Therapeutics
DYN
$4.17B
$24.1M 0.25%
672,096
– –
BMEA icon
38
Biomea Fusion
BMEA
$89.7M
$21.3M 0.22%
2,108,949
– –
BCAX
39
Bicara Therapeutics
BCAX
$1.74B
$21.2M 0.22%
+833,333
New +$21.3M
PRLD icon
40
Prelude Therapeutics
PRLD
$370M
$21M 0.22%
10,123,824
– –
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$19.6M 0.2%
1,227,178
+677,966
+123% +$8.31M
NGNE icon
42
Neurogene
NGNE
$663M
$19.1M 0.2%
456,015
– –
PRAX icon
43
Praxis Precision Medicines
PRAX
$8.21B
$18.6M 0.19%
323,105
+191,572
+146% +$10.3M
ALMS
44
Alumis Inc
ALMS
$3.4B
$16.7M 0.17%
1,562,500
– –
MRUS
45
DELISTED
Merus
MRUS
$15M 0.16%
300,000
– –
TCRX icon
46
TScan Therapeutics
TCRX
$49M
$13.9M 0.14%
2,784,792
– –
NMRA icon
47
Neumora Therapeutics
NMRA
$306M
$13.7M 0.14%
1,034,600
– –
XNCR icon
48
Xencor
XNCR
$1.48B
$13.5M 0.14%
670,431
+125,000
+23% +$2.35M
TSVT
49
DELISTED
2seventy bio
TSVT
$11.8M 0.12%
2,497,526
– –
FATE icon
50
Fate Therapeutics
FATE
$277M
$10.5M 0.11%
2,997,772
– –
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Baker Bros. Advisors held 99 positions worth $9.65B, up 23% from $7.83B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Baker Bros. Advisors's Q3 2024 filing shows 5 new, 16 increased, 3 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 833,333 shares worth $21.2M. The largest sale was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2024 buy was Bicara Therapeutics: 833,333 shares worth $21.2M.
  • Baker Bros. Advisors added most to Insmed in Q3 2024, an estimated $62M increase.
  • Baker Bros. Advisors's biggest Q3 2024 reduction was NewAmsterdam Pharma, cutting an estimated $2.01K.
  • Baker Bros. Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $28M.
  • Baker Bros. Advisors's ten largest holdings make up 78% of its $9.65B portfolio in Q3 2024.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q3 2024.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.65B.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.